Back to results
US 2013/0156691 A1Published application
Antibody Therapy
AssigneeImmunomedics, Inc.
InventorsDavid M. Goldenberg, Hans J. Hansen
Life of this patent
Estimating the term…
Abstract
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
Claims20
A method for treating a CEA expressing cancer comprising:
- a) administering to a subject with a CEA expressing cancer a naked Class I monovalent anti-CEA monoclonal antibody (MAb) or antigen-binding fragment thereof;
- b) administering to the subject either concurrently or sequentially a naked Class III anti-CEA antibody or antigen-binding fragment thereof, wherein (i) the naked Class III anti-CEA antibody or fragment thereof is unreactive with human granulocytes;
- (ii) the naked Class III anti-CEA antibody or fragment thereof has human IgG1 hinge and constant regions;
- (iii) administration of the naked Class III anti-CEA antibody or fragment thereof to a subject with a cancer that expresses CEA antigen sensitizes the cancer to the subsequent administration of a therapeutic agent;
- and
- c) administering to the subject either concurrently or sequentially at least one therapeutic agent.
3 more elements
Dependencies are inferred from the claim text.